Apollomics (APLM) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Apollomics (APLM) has outperformed XBiotech (XBIT) over the past year, gaining 16.6% versus a loss of 17.0%. XBiotech is the larger company by market cap ($66.8 million vs $62.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | XBIT |
|---|---|---|
| Share price | $21.50 | $2.19 |
| Market cap | $62.67M | $66.77M |
| 1-day change | -2.71% | +1.39% |
| YTD return | +15.00% | -8.37% |
| 1-year return | +16.64% | -17.05% |
| 5-year return | — | -83.42% |
| Forward P/E | — | 16.85 |
| EPS (TTM) | $-7.57 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.12 | $3.44 |
| 52-week low | $10.01 | $2.09 |
| Distance from 52-week high | -48.96% | -36.34% |
| Average volume | 21.85K | 39.48K |
| Shares outstanding | 2.91M | 30.49M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- APLM has outperformed XBIT by 33.7 percentage points over the past year.
APLM vs XBIT FAQ
Which is bigger, Apollomics or XBiotech?
XBiotech (XBIT) is larger, with a market capitalization of $66.77M compared with $62.67M for Apollomics (APLM).
Which stock has performed better over the past year, APLM or XBIT?
APLM returned +16.64% over the past 12 months, compared with -17.05% for XBIT (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.